NSCLC Clinical Trials in Nashville, Tennessee

14 studies are recruiting for nsclc in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Canon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

3. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

   Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Vanderbilt University Medical Center, Nashville, Tennessee

   Locations

   16 in total

   Run by

   A2 Biotherapeutics Inc.

   See if you can join NCT04981119 on ClinicalTrials.gov

4. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

   A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   38 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06343402 on ClinicalTrials.gov

5. First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

   Study STX-721-101/PFL-721CI101 is an open label, Phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (PK) exposure, and preliminary antitumor activity of STX-721/PFL-721 in participants with non-small cell lung cancer (NSCLC) carrying EGFR or HER2 exon 20 insertion (ex20ins) mutati…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners - PPDS, Nashville, Tennessee

   Locations

   25 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT06043817 on ClinicalTrials.gov

6. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

   The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   SCRI Oncology Partners - Tennessee, Nashville, Tennessee

   Locations

   153 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06881784 on ClinicalTrials.gov

7. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

   This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Normunity Investigational Site, Nashville, Tennessee

   Locations

   18 in total

   Run by

   Normunity AccelCo, Inc.

   See if you can join NCT07182149 on ClinicalTrials.gov

8. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tennessee Oncology, Nashville, Tennessee

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07397338 on ClinicalTrials.gov

9. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

   This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   54 in total

   Run by

   Merus B.V.

   See if you can join NCT03526835 on ClinicalTrials.gov

10. A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

    The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in monotherapy and in combination with standard of care (SOC) chemotherapy.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    52 in total

    Run by

    Ellipses Pharma

    See if you can join NCT05443126 on ClinicalTrials.gov

11. A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

    The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesotheli…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Locations

    12 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT06051695 on ClinicalTrials.gov

12. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Locations

    17 in total

    Run by

    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06917079 on ClinicalTrials.gov

13. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

    This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    23 in total

    Run by

    Nested Therapeutics, Inc

    See if you can join NCT06326411 on ClinicalTrials.gov

14. A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

    The goal of this Open-Label Study is to evaluate the safety and tolerability of PRTH-101 alone or in combination with pembrolizumab in adults with advance or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

    Locations

    11 in total

    Run by

    Incendia Therapeutics

    See if you can join NCT05753722 on ClinicalTrials.gov